| Literature DB >> 33461415 |
Maria Wemrell1,2, Cecilia Lenander3, Kristofer Hansson4, Raquel Vicente Perez1, Katarina Hedin3,5, Juan Merlo1,6.
Abstract
Aims: Antimicrobial resistance presents an increasingly serious threat to global public health, which is directly related to how antibiotic medication is used in society. Actions aimed towards the optimised use of antibiotics should be implemented on equal terms and according to the needs of the population. Previous research results on differences in antibiotic use between socio-economic and demographic groups in Sweden are not entirely coherent, and have typically focused on the effects of singular socio-economic variables. Using an intersectional approach, this study provides a more precise analysis of how the dispensation of antibiotic medication was distributed across socio-economic and demographic groups in Sweden in 2016-2017.Entities:
Keywords: Antibiotic medication; Sweden; antimicrobial resistance; intersectionality; socio-economic disparities
Mesh:
Substances:
Year: 2021 PMID: 33461415 PMCID: PMC9096578 DOI: 10.1177/1403494820981496
Source DB: PubMed Journal: Scand J Public Health ISSN: 1403-4948 Impact factor: 3.199
Prevalence of antibiotic dispensation in Sweden during 2016–2017 in income groups, according to age, sex and country of birth.
| Antibiotics % ( | ||||
|---|---|---|---|---|
| Low income | Medium income | High income | ||
| Age (years) | 7–14 | 20.2 (115,777) | 21.1 (110,866) | 21.2 (72,106) |
| 15–24 | 27.6 (582,198) | 28.8 (348,730) | 29.8 (155,348) | |
| 25–34 | 27.9 (545,851) | 26.4 (443,676) | 26.1 (152,555) | |
| 35–44 | 28.8 (296,866) | 27.2 (429,190) | 26.0 (432,875) | |
| 45–54 | 29.3 (394,751) | 27.0 (431,285) | 25.7 (425,807) | |
| 55–64 | 31.0 (251,527) | 31.5 (370,566) | 31.9 (492,666) | |
| 65–74 | 33.2 (125,093) | 34.6 (280,757) | 35.6 (694,624) | |
| ⩾75 | 34.7 (245,013) | 36.6 (368,542) | 39.2 (291,650) | |
| Sex | Female | 34.8 (1,372,473) | 34.8 (1,441,977) | 36.0 (1,244,236) |
| Male | 22.3 (1,184,603) | 23.9 (1,341,635) | 26.8 (1,473,395) | |
| Country of birth | Sweden | 29.0 (1,911,197) | 29.4 (2,503,427) | 30.9 (2,498,311) |
| Nordic | 30.7 (68,031) | 33.2 (74,797) | 33.0 (80,833) | |
| Europe | 27.5 (174,623) | 31.1 (92,034) | 32.7 (78,153) | |
| USA, Canada, Australia | 23.6 (7,397) | 28.5 (4,755) | 29.1 (5,683) | |
| Asia, Africa, Central and South America | 29.5 (395,828) | 30.0 (108,599) | 29.4 (54,651) | |
Prevalence ratios (PR), area under the receiver operating characteristic curve (AUC) and the incremental change in the AUC value (ΔAUC) between the models compared to model 1.
| Model 1 | Model 2 | Model 3 | Model 4 | |
|---|---|---|---|---|
|
| ||||
| 7–14 | 0.76 (0.54–0.77) | 0.76 (0.76–0.77) | 0.77 (0.76–0.78) | 0.77 (0.76–0.77) |
| 15–24 | 1.04 (1.03–1004) | 1.04 (1.03–1.05) | 1.05 (1.04–1.05) | 1.05 (1.04–1.06) |
| 25–34 | 0.99 (0.99–1.00) | 0.99 (0.99–1.00) | 1.00 (0.99–1.01) | 1.00 (0.99–1.01) |
| 35–44 | 1.00 (0.99–1.00) | 1.00 (0.99–1.00) | 1.00 (0.99–1.00) | 0.99 (0.989–1.00) |
| 45–54 | Ref. | Ref. | Ref. | Ref. |
| 55–64 | 1.16 (1.15–1.17) | 1.16 (1.15–1.16) | 1.15 (1.14–1.16) | 1.15 (1.15–1.16) |
| 65–74 | 1.29 (1.28–1.29) | 1.28 (1.27–1.29) | 1.27 (1.26–1.28) | 1.27 (1.26–1.28) |
| ⩾75 | 1.35 (1.34–1.36) | 1.31 (1.31–1.32) | 1.31 (1.31–1.32) | 1.32 (1.31–1.33) |
|
| ||||
| Female | 1.42 (1.42–1.43) | 1.43 (1.42–1.43) | 1.43 (1.42–1.43) | |
| Male | Ref. | Ref. | Ref. | |
|
| ||||
| Low | 0.97 (0.97–0.97) | 0.96 (0.96–0.97) | ||
| Middle | 0.97 (0.96–0.97) | 0.97 (0.96–0.97) | ||
| High | Ref. | Ref. | ||
|
| ||||
| Sweden | Ref. | |||
| Nordic | 0.99 (0.98–1.00) | |||
| Europe | 1.00 (0.98–1.00) | |||
| USA, Canada, Australia | 0.93 (0.90–0.97) | |||
| Asia, Africa, Central and South America | 1.05 (1.05–1.06) | |||
|
| 0.55 (0.55–0.55) | 0.59 (0.59–0.59) | 0.59 (0.59–0.59) | 0.59 (0.59–0.59) |
|
| +0.04 | +0.04 | +0.04 | |
Values are point estimations and 99% confidence intervals (CI) obtained from Cox regression modelling antibiotic prescription in relation to age, sex, income and country of birth.
Results from model 5, including the intersectional categorical variable.
| Age (years) | Sex | Income | Country of birth | PR (99% CI) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7–14 | 15–24 | 25–34 | 35–44 | 45–54 | 55–64 | 65–74 | ⩾75 | F | M | Low | Mid | High | Swe | Nord | Eur | USA, Canada, Australia | Africa, Asia, Central and South America | |
| 0.63 (0.47–0.86) | ||||||||||||||||||
| 0.64 (0.48–0.87) | ||||||||||||||||||
| 0.66 (0.53–0.82) | ||||||||||||||||||
| 0.66 (0.6–0.73) | ||||||||||||||||||
| 0.67 (0.53–0.85) | ||||||||||||||||||
| 0.70 (0.32–1.52) | ||||||||||||||||||
| 0.71 (0.41–1.25) | ||||||||||||||||||
| 0.72 (0.54–0.95) | ||||||||||||||||||
| 0.73 (0.64–0.84) | ||||||||||||||||||
| 0.74 (0.65–0.84) | ||||||||||||||||||
| 1.81 (1.45–2.24) | ||||||||||||||||||
| 1.83 (1.75–1.91) | ||||||||||||||||||
| 1.84 (1.74–1.95) | ||||||||||||||||||
| 1.87 (1.47–2.39) | ||||||||||||||||||
| 1.87 (1.71–2.06) | ||||||||||||||||||
| 1.88 (1.85–1.91) | ||||||||||||||||||
| 1.89 (1.54–2.33) | ||||||||||||||||||
| 1.91 (1.81–2.01) | ||||||||||||||||||
| 2.02 (1.68–2.43) | ||||||||||||||||||
| 2.03 (1.61–2.55) | ||||||||||||||||||
|
| 0.60 (0.60-0-60) | |||||||||||||||||
|
| +0.05. | |||||||||||||||||
Values are PR with 99% CI for the 10 intersectional strata with the highest and lowest PR for antibiotic dispensation, compared with the reference stratum (i.e. 45- to 54-year-old men born in Sweden with a high income). The table also presents the value of the AUC with 95% CI and the ΔAUC compared to model 1 (Table II). Only the 10 intersectional strata with the highest and lowest PRs are shown.
Figure 1.Prevalence of antibiotic dispensation in Sweden during 2016–2017, all intersectional strata.